Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Buys $11,400.00 in Stock

Abeona Therapeutics Inc (NASDAQ:ABEO) SVP Brendan M. O’malley acquired 3,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The shares were purchased at an average price of $3.80 per share, with a total value of $11,400.00. Following the acquisition, the senior vice president now owns 187,421 shares of the company’s stock, valued at approximately $712,199.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Abeona Therapeutics Price Performance

NASDAQ ABEO traded up $0.05 during trading hours on Tuesday, reaching $3.72. 17,486 shares of the company’s stock were exchanged, compared to its average volume of 163,779. The company’s 50-day moving average is $3.74 and its two-hundred day moving average is $3.49. Abeona Therapeutics Inc has a one year low of $2.19 and a one year high of $5.80.

Abeona Therapeutics (NASDAQ:ABEO) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.66) by $0.22. The company had revenue of $3.50 million for the quarter. Analysts anticipate that Abeona Therapeutics Inc will post -1.99 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. StockNews.com initiated coverage on shares of Abeona Therapeutics in a report on Thursday, August 17th. They issued a “hold” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $38.00 target price on shares of Abeona Therapeutics in a report on Thursday, August 24th.

Institutional Trading of Abeona Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its position in shares of Abeona Therapeutics by 30.6% during the second quarter. Goldman Sachs Group Inc. now owns 213,282 shares of the biopharmaceutical company’s stock worth $860,000 after buying an additional 50,008 shares during the period. State Street Corp boosted its position in Abeona Therapeutics by 18.0% during the 2nd quarter. State Street Corp now owns 51,095 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 7,800 shares during the last quarter. BlackRock Inc. grew its stake in shares of Abeona Therapeutics by 156.2% during the 2nd quarter. BlackRock Inc. now owns 142,785 shares of the biopharmaceutical company’s stock worth $575,000 after acquiring an additional 87,057 shares in the last quarter. Northern Trust Corp raised its holdings in shares of Abeona Therapeutics by 206.4% in the second quarter. Northern Trust Corp now owns 103,235 shares of the biopharmaceutical company’s stock valued at $416,000 after purchasing an additional 69,539 shares during the last quarter. Finally, Citigroup Inc. acquired a new stake in shares of Abeona Therapeutics in the second quarter valued at approximately $806,000. Institutional investors and hedge funds own 43.97% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.